R J Bio-Tech
In the Mar 2018 quarter, revenue was ₹2 Cr, against under ₹1 Cr a year earlier and net profit was −₹17 Cr, against −₹13 Cr a year earlier (compared with Mar 2017). Promoters held 60.32% of R J Bio-Tech in Mar 2022, unchanged from Sep 2021.
Peer Comparison
Fast Moving Consumer Goods › Agricultural Food & other Products › Other Agricultural Products
| ₹379.70 | 20.59 | 13,185 Cr | 2.69 | 0.77% | 13.83% | 18.52% | 12,166 Cr | 640 Cr | |
| ₹349.70 | 10.56 | 8,004 Cr | 1.38 | 1.26% | 11.16% | 14.81% | 6,137 Cr | 758 Cr | |
| ₹143.76 | 15.85 | 6,594 Cr | 1.84 | 0.21% | 9.23% | 12.46% | 6,110 Cr | 416 Cr | |
| ₹686.65 | 14.15 | 3,532 Cr | 1.74 | 0.73% | 16.86% | 17.00% | 1,302 Cr | 249 Cr | |
| ₹375.10 | 20.58 | 3,217 Cr | 1.99 | 0.00% | 6.14% | 10.77% | 2,823 Cr | 159 Cr | |
| ₹91.10 | 23.36 | 1,888 Cr | 3.15 | 0.51% | 12.56% | 20.24% | 1,899 Cr | 77 Cr | |
R J Bio-Tech (this company) | ₹3.43 | — | — | — | — | — | — | 25 Cr | — |
| Median 7 companies | ₹349.70 | 18.22 | 5,063 Cr | 1.92 | 0.62% | 11.86% | 15.91% | 2,823 Cr | 333 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Weaknesses
1- Company has low interest coverage ratio.
Technical Indicators
Oscillators
Neutral
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
Quarterly Results
| Particulars | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5 | 7 | 2 | 15 | 11 | 6 | 4 | 0 | 0 | 0 | 7 | 0 | 2 |
| Expenses | 4 | 6 | 2 | 13 | 7 | 4 | 6 | 0 | 11 | 0 | 9 | 0 | 8 |
| Operating Profit | 1 | 2 | 0 | 2 | 4 | 2 | -3 | 0 | -11 | 0 | -1 | 0 | -6 |
| OPM % | 22% | 21% | -22% | 16% | 37% | 33% | -73% | — | -11922% | — | -20% | 100% | -374% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 2 | 0 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 1 | -2 | 1 | 3 | 1 | -4 | 0 | -13 | 0 | -3 | 0 | -17 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — | 0% | — | 0% | — | 0% |
| Net Profit | 0 | 1 | -2 | 1 | 3 | 1 | -4 | 0 | -13 | 0 | -3 | 0 | -17 |
| EPS (₹) | 0.1 | 0.67 | -1.84 | 1.55 | 3.36 | 1.21 | -3.74 | 0 | -13.54 | 0 | -3.54 | 0 | -18.39 |
Profit & Loss
| Particulars | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.39 | 23.14 | 24.63 | 29.69 | 11.91 | 7.04 | 7.73 | 10.21 | 12.65 | 11.34 | 0 | 0 |
| Expenses | 14.38 | 17.18 | 18.86 | 23.53 | 23.07 | 14.93 | 15.11 | 13.7 | 25.27 | 10.02 | 0.79 | 0.01 |
| Operating Profit | 4.01 | 5.96 | 5.77 | 6.16 | -11.16 | -7.89 | -7.38 | -3.49 | -12.62 | 1.32 | -0.79 | -0.01 |
| OPM % | 21.81% | 25.76% | 23.43% | 20.75% | -93.7% | -112.07% | -95.47% | -34.18% | -99.76% | 11.64% | — | — |
| Other Income | 0 | 0 | 0 | 0 | 0.06 | -8.69 | 0.14 | 0.21 | -2.97 | 0.52 | 0.55 | 0 |
| Interest | 2.34 | 2.64 | 3.6 | 3.44 | 3.6 | 3.89 | 4.14 | 0.78 | 0 | 5.82 | 0 | 0 |
| Depreciation | 0.36 | 0.45 | 0.7 | 0.44 | 0.32 | 0.3 | 0.15 | 0.1 | 0.09 | 0.07 | 0.01 | 0.01 |
| PBT | 1.31 | 2.87 | 1.47 | 2.28 | -15.02 | -20.77 | -11.53 | -4.16 | -15.68 | -4.05 | -0.25 | -0.02 |
| Tax % | 0% | 0% | 0% | 0.44% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 1.3 | 2.87 | 1.46 | 2.27 | -15.02 | -20.77 | -11.53 | -4.16 | -15.68 | -4.05 | -0.25 | -0.01 |
| EPS (₹) | 1.87 | 3.03 | 1.54 | 2.4 | -15.86 | -21.94 | -12.18 | -4.39 | -16.56 | -4.28 | -0.26 | -0.01 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.97 | 9.47 | 9.47 | 9.47 | 9.47 | 9.47 | 9.47 | 9.47 | 9.47 | 9.47 | — | — |
| Reserves | 7.51 | 12.88 | 14.23 | 16.5 | 1.49 | -19.28 | -30.81 | -34.97 | -50.65 | -59.81 | — | — |
| Borrowings | 19.8 | 24.77 | 26.81 | 24.86 | 29.63 | 37.25 | 41.5 | 42.1 | 40.54 | 51.14 | — | — |
| Other Liabilities | 6.28 | 10.9 | 10.36 | 9.06 | 6.94 | 7.64 | 7.62 | 8.82 | 6.5 | 1.11 | — | — |
| Total Liabilities | 40.56 | 58.02 | 60.87 | 59.89 | 47.53 | 35.08 | 27.78 | 25.42 | 5.86 | 1.91 | — | — |
| Fixed Assets | 2.91 | 2.99 | 2.41 | 2.12 | 1.95 | 1.84 | 1.75 | 1.72 | 1.75 | 1.53 | — | — |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Other Assets | 37.65 | 55.03 | 58.46 | 57.77 | 45.58 | 33.24 | 26.03 | 23.7 | 4.11 | 0.38 | — | — |
| Total Assets | 40.56 | 58.02 | 60.87 | 59.89 | 47.53 | 35.08 | 27.78 | 25.42 | 5.86 | 1.91 | — | — |
Cash Flow
| Particulars | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 3.88 | -5.12 | 2.47 | 5.79 | 0.07 | -2.69 | 0.84 | 0.71 | 1.96 | -4.72 | 0.7 | -0.8 |
| Investing | -2.37 | -2.18 | -1.66 | -1.35 | -0.84 | -0.82 | -0.77 | -0.67 | -0.37 | 0 | 0.09 | 0 |
| Financing | -2.67 | 7.63 | -0.95 | -4.84 | 0.82 | 3.45 | -0.03 | -0.06 | -1.54 | 4.68 | 0 | 0 |
| Net Cash Flow | -1.16 | 0.33 | -0.14 | -0.4 | 0.05 | -0.05 | 0.04 | -0.02 | 0.05 | -0.04 | 0.79 | -0.8 |
| Free Cash Flow | 3.66 | -5.53 | 2.35 | 5.76 | 0.09 | -2.77 | 0.78 | 0.64 | 1.85 | -4.72 | 0.79 | -0.8 |
| CFO/OP | 101 | -86 | 43 | 94 | -1 | 34 | -11 | -20 | -16 | -386 | -89 | 8,000 |
Ratios
| Particulars | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 172 | 179 | 238 | 294 | 582 | 863 | 473 | 263 | 23.95 | 9.01 | — | — |
| Inventory Days | 1,123 | 1,198 | 1,368 | 765 | 689 | 637 | 798 | 837 | 30.46 | 0 | — | — |
| Days Payable | 45.83 | 115 | 107 | 63.88 | 54.78 | 157 | 151 | 170 | 11.6 | — | — | — |
| Cash Conversion Cycle | 1,249 | 1,263 | 1,498 | 995 | 1,216 | 1,342 | 1,121 | 930 | 42.8 | 9.01 | — | — |
| Working Capital Days | 237 | 304 | 318 | 276 | 282 | -390 | -892 | -820 | -1,129 | -1,547 | — | — |
| ROCE % | 10.95% | 13.54% | 10.39% | 11.29% | -25.11% | -23.67% | -31.05% | -18.88% | -159.27% | 2400% | — | — |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view R J Bio-Tech insights
56 extracted metrics + investor summaries across FY12–FY24.
Documents
Frequently Asked Questions about R J Bio-Tech
What does R J Bio-Tech Ltd do?
Where is R J Bio-Tech Ltd (RJBIOTECH) listed?
Which sector does R J Bio-Tech Ltd belong to?
Company Information
Incorporated in 2005, R J Biotech Limited develops proprietary hybrids with nutritional and economical traits in Fiber crops, Cereal crops and Vegetable crops
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/536456.md for R J Bio-Tech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.